These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 33545803)

  • 1. Imipenem-resistant Pseudomonas aeruginosa treated with piperacillin/tazobactam in a patient with severe pneumonia: a case report and related literature review.
    He L; He A; Qian Y
    Ann Palliat Med; 2021 Jan; 10(1):810-817. PubMed ID: 33545803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of drug resistance of Pseudomonas aeruginosa and use of antibiotics in burn wards during 6 years].
    Dou Y; Zhang Q
    Zhonghua Shao Shang Za Zhi; 2014 Feb; 30(1):9-14. PubMed ID: 24684983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
    Wang H; Chen MJ;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study.
    Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Abdel Fattah M; Haquin J; Macgowan A; Grier S; Gibbs J; Chazan B; Yanovskay A; Ben Ami R; Landes M; Nesher L; Zaidman-Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Mauer S; Rodriguez-Bano J; Morales I; Oliver A; Ruiz De Gopegui E; Cano A; Machuca I; Gozalo-Marguello M; Martinez Martinez L; Gonzalez-Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller-Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstein Y; Leibovici L; Yahav D
    Clin Infect Dis; 2020 May; 70(11):2270-2280. PubMed ID: 31323088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent.
    Gill CM; Nicolau DP;
    Clin Ther; 2023 Jan; 45(1):72-77. PubMed ID: 36593150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 7. [Risk factors of nosocomial infections caused by piperacillin-tazobactam resistant Pseudomonas aeruginosa].
    Djordjević Z; Gajović O; Mijailović Z; Ilić A; Stolić R
    Srp Arh Celok Lek; 2013; 141(9-10):640-7. PubMed ID: 24364227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.
    Jaccard C; Troillet N; Harbarth S; Zanetti G; Aymon D; Schneider R; Chiolero R; Ricou B; Romand J; Huber O; Ambrosetti P; Praz G; Lew D; Bille J; Glauser MP; Cometta A
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2966-72. PubMed ID: 9797234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification and Drug Resistance Analysis of Pathogenic Bacteria in Patients with Bacterial Pneumonia in Emergency Intensive Care Unit.
    Yin K; Liu L; Fan G
    Contrast Media Mol Imaging; 2022; 2022():6980091. PubMed ID: 36262997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
    J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chinese expert consensus on the management of lower respiratory tract infections of
    Pulmonary Infection Assembly of Chinese Thoracic Society
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Aug; 45(8):739-752. PubMed ID: 35927044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
    Mirza HC; Hortaç E; Koçak AA; Demirkaya MH; Yayla B; Güçlü AÜ; Başustaoğlu A
    J Glob Antimicrob Resist; 2020 Mar; 20():334-338. PubMed ID: 31568882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam.
    Mokaddas EM; Sanyal SC
    J Chemother; 1999 Apr; 11(2):93-6. PubMed ID: 10326738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antimicrobial resistance monitoring of gram-negative bacilli isolated from 15 teaching hospitals in 2014 in China].
    Wang Q; Wang H; Yu Y; Xu X; Sun Z; Lu J; Yang B; Zhang L; Hu Z; Feng X; Xu Y; Ni Y; Mei Y; Liao K; Ji P; Chu Y
    Zhonghua Nei Ke Za Zhi; 2015 Oct; 54(10):837-45. PubMed ID: 26675021
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
    Sun HK; Kuti JL; Nicolau DP
    Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro interaction of various antibiotic combinations recommended by Chinese consensus statement against carbapenems-resistant Pseudomonas aeruginosa.
    Ma W; Li J; Wang D; Yu C; Sun S
    Lett Appl Microbiol; 2019 Sep; 69(3):198-203. PubMed ID: 31236975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
    Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
    Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
    Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
    Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.